Irish Prostate Cancer Outcomes Research (IPCOR)

The Irish Prostate Cancer Outcomes Research (IPCOR) study was established in 2014 to assess the experience of prostate cancer patients and their quality of life, and also to benchmark the quality of prostate cancer care in Ireland against international experience. IPCOR is a €1.75 million collaborative cancer research initiative of the Irish Cancer Society and Movember Foundation that will ultimately lead to improved care and outcomes in prostate cancer care in Ireland.

IPCOR involves the National Cancer Registry Ireland, the HRB Clinical Research Facility in Galway, the National Cancer Control Programme and major academic institutions represented by Clinical Research Development Ireland (CRDI).

Through this initiative, researchers will, for the first time, collect data on clinical and patient-reported outcomes of hundreds of men who have been newly diagnosed with prostate cancer across 17 Irish hospitals over a five-year period.

Participants will be asked about their experience of prostate cancer care, their physical and psychological wellbeing, and their quality of life before, during, and after treatment.

Why is IPCOR collecting data?

Using this information, IPCOR will establish a registry that will better inform future care delivery and our knowledge of the disease, which sees more than 3,000 new cases being diagnosed in Ireland every year.
Ultimately the IPCOR registry will improve patient experiences and maximise quality of life for men diagnosed with prostate cancer in Ireland by informing doctors, hospitals and policymakers about future healthcare decisions and also promoting equal access to services and improvements in care nationally.

IPCOR is supported by: